# US 2005/0232985 A1 · Ciprofloxacin hcl

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232985 A1
- Document ID: US20050232985A1
- Status: Published application
- Kind: A1
- Application number: 10/519,467
- Filed: 2004-12-27
- Published: 2005-10-20
- Earliest claimed: 2002-06-27
- Inventors: Robert Janitzek
- Web page: https://patentgrep.com/patent/US20050232985A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to Ciprofloxacin Hydrochloride-containing composition, useful for the treatment of diseases. In particular, it relates to pharmaceutical composition comprising the following essential components: i) Ciprofloxacin Hydrochloride; ii) Magnesium stearate; iii) Starch; and iv) Carboxymethylstach Sodium.

## Claims

### Claim 1

A pharmaceutical composition comprising the following essential components:
i. Ciprofloxacin Hydrochloride;
ii. Magnesium stearate;
iii. Starch; and
iv. Carboxymethylstach Sodium

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, the Ciprofloxacin Hydrochloride being in the amount of about 300 g of the composition.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, the Magnesium stearate being in the amount of about 4 g of the composition.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, the starch being in the amount of about 65 g of the composition.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, the Carboxymethylstach being in the amount of 18 g of the composition.

### Claim 6

A process for the preparation of a pharmaceutical composition containing Ciprofloxacin Hydrochloride comprising the following steps:
i. Mixing the appropriate prescription amount of Ciprofloxacin Hydrochloride, Starch and Carboxymethylstach into a container;
ii. Adding some amount of starch thick liquid and stir until a soft material is obtained;
iii. Granulating the soft material formed in the previous step and then dry at a temperature of 70° C. for 4 hours;
iv. Take it out and arrange the grain;
v. Adding some amount of Magnesium Stearate in order to fill well.

### Claim 7 (depends on 1)

Use of the pharmaceutical composition according to claim 1 for the treatment of upper respiratory tract infections including tonsillitis, sinusitis, otitis media and pharynx inflammation; lower respiratory tract infections including acute and chronic bronchitis, bronchiectasis and pneumonia; urinary tract infections including urethritis, cystitis, pyelonephritis, prostates and pelvic inflammatory; gastrointestinal infections including enteric fever and infective diarrhea; skin and soft tissue infections; wounds infections; and infections caused by other sensitive bacteria.
